(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
`(19) World Intellectual Property Organization
`International Bureau
`
`( 43) International Publication Date
`26 June 2008 (26.06.2008)
`
`PCT
`
`(10) International Publication Number
`WO 2008/077155 Al
`(81) Designated States ( unless othenvise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,
`CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,
`ES, FI, GB, GD, GE, GH, GM, GT, HN, HR. HU, ID, IL,
`IN, IS, .JP, KE, KG, KM, KN, KP. KR, KZ, LA, LC, LK,
`LR, LS, LT, LU, LY, MA, MD. ME, MG, MK, l'vlN, MW,
`MX. MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
`PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY,
`TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ. VC, VN, ZA,
`ZM, ZW.
`
`(84) Designated States (unless othenvise indicated, for every
`kind of regional protection available): ARIPO (BW, GH,
`GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
`ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
`European (AT, HE, HG, CIL CY, CZ, DE, DK, EE, ES, FI,
`FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,
`PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
`GA, GN, GQ, GW, ML, MR, NE. SN, TD, TG).
`
`Published:
`with international search report
`before the expiration of the time limit for amending the
`claims and to be republished in the event of receipt of
`amendments
`
`(51) International Patent Classification:
`A61L 2/00(2006.01)
`A61L 2/20 (2006.01)
`
`(21) International Application Number:
`PCT /US2007 /088728
`
`(22) International Filing Date:
`21 December 2007 (21.12.2007)
`
`(25) Filing Language:
`
`(26) Publication Language:
`
`English
`
`English
`
`(30) Priority Data:
`60/871,426
`
`21 December 2006 (21.12.2006) US
`
`(71) Applicant (for all designated States except US): GENEN(cid:173)
`TECH, INC. [US/US]; 1 DNA Way, South San Francisco,
`CA 94080-4990 (US).
`
`(72) Inventors; and
`(75) Inventors/Applicants (for US only): LAM, Xanthe, M.
`[US/US]; 662 Orchid Drive, South San Francisco, CA
`94080 (US). NGUYEN, Tue [US/US]; 16 Woodleaf Ave.,
`Redwood City, CA 94061 (lJS).
`
`(74) Agent: KALINOWSKI, Grant; Genentech, Inc., 1 DNA
`Way, South San Francisco, CA 94080 (US).
`
`----iiiiiii
`iiiiiii -iiiiiii
`iiiiiii -!!!!!!!!
`
`-iiiiiii
`iiiiiii ------
`
`~ <
`an an
`
`~
`t'(cid:173)
`t'-
`0 --..
`QO
`0
`0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
`N
`(54) Title: STERILIZATION OF OBJECTS CONTAINING BIOLOGICAL MOLECULES
`~ (57) Abstract: The invention relates to methods for surface-sterilizing objects containing ethylene-oxide-sensitive, temperature(cid:173)
`
`~ sensitive compounds, including biological molecules.
`
`Regeneron Exhibit 1029.001
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`STERILIZATION OF OBJECTS CONTAINING BIOLOGICAL MOLECULES
`
`5
`
`Cross-Reference to Related Applications
`
`This application claims the benefit of U.S. Provisional Application No. 60/871,426,
`
`filed December 22, 2007, which is incorporated by reference in its entirety.
`
`10
`
`The invention relates to methods for surface-sterilizing objects containing ethylene(cid:173)
`
`oxide-sensitive, temperature-sensitive compounds, including biological molecules.
`
`Field of Invention
`
`Background of Invention
`
`Objects used in medical applications are generally sterilized before use. Sterilization
`
`15
`
`can be accomplished by a variety of methods including, e.g., steam sterilization, radiation
`
`sterilization, gas sterilization (e.g. with ethylene oxide), and chemical sterilization. However,
`
`these treatments cannot be used for objects containing pharmaceutical compositions because
`
`their active ingredients are typically sensitive to them. For example, steam and gas
`
`sterilization are generally performed at high temperatures (approx. 45°C to 55°C or higher)
`
`20
`
`that damage certain active ingredients in phannaceutical compositions. Similarly, the agents
`
`used for radiation or chemical sterilization generally cause chemical damage to the active
`
`ingredients. Consequently, pharmaceutical compositions are generally sterilized by an
`
`alternative method, e.g. by filtration, and then packaged into separately sterilized objects.
`
`Because of the complexity of this process, it is difficult to also ensure the sterility of the
`
`25
`
`surfaces of the objects.
`
`In many circumstances it would be advantageous to sterilize the surfaces of these
`
`objects in order to reduce the risk of contamination during subsequent handling. For
`
`example, there is an increased risk of endophthalmitis after intraocular injection if the surface
`
`of the syringe used for injection is not sterilized. Thus, there remains a need for efficient and
`
`30
`
`cost-effective methods of surface-sterilizing objects containing ethylene-oxide-sensitive,
`
`temperature-sensitive compounds, such as biological molecules, without a significant adverse
`
`effect on their activity or integrity.
`
`Regeneron Exhibit 1029.002
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`Summary of the Invention
`
`The invention relates to methods for surface-sterilizing objects containing ethylene(cid:173)
`
`oxide-sensitive, temperature-sensitive compounds, such as biological molecules. The
`
`invention is based, in part, on the surprising discovery of ethylene-oxide-based sterilization
`
`5
`
`conditions that will effectively sterilize the surface of an object but which do not significantly
`
`damage ethylene-oxide-sensitive, temperature-sensitive compounds contained inside.
`
`In one aspect, the invention provides a method for surface-sterilizing an object having
`
`an ethylene-oxide(EtO)-impermeable interior space containing a compound with a
`
`temperature-sensitive and EtO-sensitive activity by exposing the object to EtO under
`
`10
`
`conditions such that the object is surface-sterilized and the compound retains at least 50% of
`
`said activity. In some embodiments, the conditions comprise: a) temperature between 25°C
`
`and 35°C; b) EtO concentration of between 300 mg/Land 800 mg/L; and c) relative humidity
`
`between 45% and 60%; for between 1 and 6 hours. In some embodiments, the conditions
`
`comprise: a) temperature between 27°C and 33°C; b) EtO concentration of between 300
`
`15 mg/Land 600 mg/L; and c) relative humidity between 48% and 52%; for between 1 and 6
`
`hours. In some embodiments, the conditions comprise: a) temperature of30°C; b) EtO
`
`concentration of 600 mg/L; and c) relative humidity of 50%; for 1, 1.5 or 2 hours.
`
`In some embodiments, the compound retains at least 90% of said activity. In some
`
`embodiments, the compound is a polypeptide, e.g. an antibody, which includes monoclonal
`
`20
`
`antibodies, chimeric antibodies, humanized antibodies or human antibodies. In some
`
`embodiments where the compound is a polypeptide, the percent alkylation of the polypeptide
`
`is not statistically different from a control polypeptide not exposed to EtO. In some
`
`embodiments, the antibody is an antigen-binding fragment, e.g. a Fab fragment. In some
`
`embodiments, the Fab fragment binds VEGF, e.g. ranibizumab (LUCENTIS:J{)).
`
`25
`
`In some embodiments, the compound is present in an aqueous pharmaceutical
`
`composition, e.g. a composition comprising at least one of: an amino acid, a disaccharide
`
`and a non-ionic surfactant. In some embodiments the pharmaceutical composition comprises
`
`histidine, trehalose and polysorbate 20.
`
`In some embodiments, the object is a syringe. In some embodiments the syringe
`
`30
`
`comprises glass and comprises a stopper comprising D777-7 laminated with FluroTec®; and
`
`a tip cap comprising D777-7 laminated with Fluro Tee([, or D2 l -7 H laminated with
`
`FluroTec@:. In some embodiments, the object is contained within a package comprising an
`
`EtO-permeable material, e.g. TYVEK®.
`
`2
`
`Regeneron Exhibit 1029.003
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`In another aspect, the invention provides an object produced by a method of the
`
`invention.
`
`Detailed Description of the Invention
`
`5
`
`Unless defined otherwise, all technical and scientific terms used herein have the same
`
`meaning as is commonly understood by one of ordinary skill in the relevant art. All patents
`
`and publications mentioned herein are expressly incorporated by reference in their entireties
`
`for all purposes.
`
`Throughout this specification and claims, the word "comprise," or variations such as
`
`10
`
`"comprises" or "comprising," indicate the inclusion of any recited integer or group of
`
`integers but not the exclusion of any other integer or group of integers.
`
`As used herein, a "compound" is any molecule that has an activity which can be
`
`measured. Compounds according to the present invention generally have a pharmacological
`
`activity. For example, the activity of a compound may include the ability to bind to a
`
`15
`
`particular molecule, to inhibit (or enhance) an enzymatic activity, induce a particular
`
`physiological response, etc.
`
`As used herein, an "ethylene-oxide-impermeable" or "EtO-impermeable" object is
`
`one in which no more than 0.5 ppm EtO is present inside the object after EtO sterilization.
`
`As EtO-impermable object my comprise, e.g., glass and/or certain plastics.
`
`20
`
`As used herein, an activity is "ethylene-oxide-sensitive" or "EtO-sensitive" when the
`
`activity is reduced following exposure to ethylene oxide (EtO). In some embodiments, the
`
`exposure is to 10 ppm EtO at 30°C for 3 days. In some embodiments, the activity is reduced
`
`by at least 90% following EtO exposure. In some embodiments, the activity is reduced by
`
`less that 90%, e.g. at least 80%, 70%, 60% or 50%.
`
`25
`
`As used herein, "percent alkylation" in the context of a polypeptide is the percentage
`
`of polypeptide that is in the basic peak relative to polypeptide that is in the acidic or main
`
`peaks as measured by IEC.
`
`As used herein, an activity is "temperature-sensitive" when the activity is reduced
`
`following exposure to a high temperature, e.g. above room temperature. Tn some
`
`30
`
`embodiments, the exposure is for 2 hours. In some embodiments, the activity is reduced
`
`following exposure to temperatures of at least 30°C, e.g. at least 35°C, 40°C, 45°C, 50°C,
`
`55°C or 60°C. Tn some embodiments, the activity is reduced by at least 90% following
`
`exposure to a high temperature. In some embodiments, the activity is reduced by less that
`
`3
`
`Regeneron Exhibit 1029.004
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`90%, e.g. at least 80%, 70%, 60% or 50%. In some embodiments, the activity is reduced by
`
`at least 5% or at least 1 %.
`
`As used herein, the surfact of an object is "sterilized" when the amount of at least one
`
`biological contaminant present on the surface of the object being treated according to the
`
`5
`
`present invention is reduced following the treatment. Typically, the amount is reduced by at
`
`least one log (i.e. by at least 10-fold). In some embodiments of the invention, the amount is
`
`reduced by 2 logs, 3 logs, 4 logs, 5 logs, or 6 logs.
`
`As used herein, a "biological contaminant" is a contaminant that, upon direct or
`
`indirect contact with a biological material, may have a deleterious effect on the biological
`
`10 material. Examples of biological contaminants include viruses; bacteria or bacterial spores;
`
`parasites; yeasts; molds; mycoplasmas; and prions. Further, a biological contaminant need
`
`not be naturally or accidentally present. For example, a biological contaminant may be
`
`Bacillus subtilis spores deliberately placed on the surface of an obj eet to be sterilized in order
`
`to monitor the success of the sterilization.
`
`15
`
`As used herein, a "subject" is a human subject or patient.
`
`As used herein, a "polypeptide" is broadly defined and includes both short
`
`polypeptides as well as longer polypeptides such as proteins and protein fragments. For
`
`example, the term polypeptide may include from dipeptides, tripeptides, and the like to
`
`enzymes, hormones, antibodies or any fragments of these that has an activity.
`
`20
`
`As used here, the te1m "antibody" is used in the broadest sense and specifically covers
`
`monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific
`
`antibodies), and antibody fragments, so long as they exhibit the desired biological activity.
`
`The term "monoclonal antibody" as used herein refers to an antibody from a
`
`population of substantially homogeneous antibodies, i.e., the individual antibodies
`
`25
`
`comprising the population are identical and/or bind the same epitope(s), except for possible
`
`variants that may arise during production of the monoclonal antibody, such variants generally
`
`being present in minor amounts. Such monoclonal antibody typically includes an antibody
`
`comprising a polypeptide sequence that binds a target, wherein the target-binding polypeptide
`
`sequence was obtained by a process that includes the selection of a single target binding
`
`30
`
`polypeptide sequence from a plurality of polypeptide sequences. For example, the selection
`
`process can be the selection of a unique clone from a plurality of clones, such as a pool of
`
`hybridoma clones, phage clones or recombinant DNA clones. It should be understood that
`
`the selected target binding sequence can be further altered, for example, to improve affinity
`
`4
`
`Regeneron Exhibit 1029.005
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`for the target, to humanize the target binding sequence, to improve its production in cell
`
`culture, to reduce its immunogenicity in vivo, to create a multispecific antibody, etc., and that
`
`an antibody comprising the altered target binding sequence is also a monoclonal antibody of
`
`this invention. In contrast to polyclonal antibody preparations which typically include
`
`5
`
`different antibodies directed against different determinants ( cpitopcs ), each monoclonal
`
`antibody of a monoclonal antibody preparation is directed against a single determinant on an
`
`antigen. In addition to their specificity, monoclonal antibody preparations are advantageous
`
`in that they are typically uncontaminated by other immunoglobulins. The modifier
`
`"monoclonal" indicates the character of the antibody as being obtained from a substantially
`
`10
`
`homogeneous population of antibodies, and is not to be construed as requiring production of
`
`the antibody by any particular method. For example, the monoclonal antibodies to be used in
`
`accordance with the present invention may be made by a variety of techniques, including, for
`
`example, the hybridoma method (e.g., Kohler et al., Nature, 256:495 (1975); Harlow et al.,
`
`Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988);
`
`15
`
`Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681, (Elsevier,
`
`N.Y., 1981 )), recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567), phage
`
`display technologies (see, e.g., Clackson et al., Nature, 352:624-628 (1991); Marks et al., J.
`
`Mal. Biol., 222:581-597 (1991); Sidhu et al., J. Mal. Biol. 338(2):299-310 (2004); Lee et al.,
`
`J.Mol.Biol.340(5):1073-1093 (2004); Fellouse, Proc. Nat. Acad. Sci. USA 101(34):12467-
`
`20
`
`12472 (2004); and Lee et al. J. lmmunol. Methods 284(1-2): 119-132 (2004), and technologies
`
`for producing human or human-like antibodies in animals that have parts or all of the human
`
`immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., WO
`
`1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741; Jakobovits et al., Proc.
`
`Natl. A cad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993);
`
`25
`
`Bruggemann et al., Year in Immuno., 7:33 (1993); U.S. Patent Nos. 5,545,806; 5,569,825;
`
`5,591,669 ( all of GenPharm); U.S. Patent No. 5,545,807; WO 1997 /17852; U.S. Patent Nos.
`
`5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016; Marks et al.,
`
`Bio/Technology, 10: 779-783 (1992); Lonberg et al., Nature, 368: 856-859 (1994); Monison,
`
`Nature, 368: 812-813 (I 994); Fishwild et al., Nature Biotechnology, 14: 845-85 I (1996);
`
`30 Neuberger, Nature Biotechnology, 14: 826 (1996); and Lonberg and Huszar, Intern. Rev.
`
`Immunol., 13: 65-93 (1995)).
`
`The monoclonal antibodies herein specifically include "chimeric" antibodies in which
`
`a portion of the heavy and/or light chain is identical with or homologous to corresponding
`
`5
`
`Regeneron Exhibit 1029.006
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`sequences in antibodies derived from a particular species or belonging to a particular
`
`antibody class or subclass, while the remainder of the chain( s) is identical with or
`
`homologous to corresponding sequences in antibodies derived from another species or
`
`belonging to another antibody class or subclass, as well as fragments of such antibodies, so
`
`5
`
`long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison
`
`et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest
`
`herein include "primatized" antibodies comprising variable domain antigen-binding
`
`sequences derived from a non-human primate (e.g. Old World Monkey, Ape etc) and human
`
`constant region sequences, as well as "humanized" antibodies.
`
`10
`
`"Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies
`
`that contain minimal sequence derived from non-human immunoglobulin. For the most part,
`
`humanized antibodies are human immunoglobulins (recipient antibody) in which residues
`
`from a hypcrvariablc region of the recipient arc replaced by residues from a hypcrvariablc
`
`region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman
`
`15
`
`primate having the desired specificity, affinity, and capacity. In some instances, framework
`
`region (FR) residues of the human immunoglobulin are replaced by corresponding non(cid:173)
`
`human residues. Furthermore, humanized antibodies may comprise residues that are not
`
`found in the recipient antibody or in the donor antibody. These modifications are made to
`
`further refine antibody performance. In general, the humanized antibody will comprise
`
`20
`
`substantially all of at least one, and typically two, variable domains, in which all or
`
`substantially all of the hypcrvariablc loops correspond to those of a non-human
`
`immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin
`
`sequence. The humanized antibody optionally also will comprise at least a portion of an
`
`immunoglobulin constant region (Fe), typically that ofa human immunoglobulin. For further
`
`25
`
`details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329
`
`(1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).
`
`"Antibody fragments" comprise a portion of an intact antibody, preferably comprising
`
`the antigen binding region thereof ("an antigen-binding fragment"). Examples of antibody
`
`fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-
`
`30
`
`chain antibody molecules; and multispecific antibodies formed from antibody fragment(s).
`
`Papain digestion of antibodies produces two identical antigen-binding fragments,
`
`called "Fab" fragments, each with a single antigen-binding site, and a residual "Fe" fragment,
`
`6
`
`Regeneron Exhibit 1029.007
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`whose name reflects its ability to crystallize readily. Pepsin treatment yields an F( ab ')2
`
`fragment that has two antigen-binding sites and is still capable of cross-linking antigen.
`
`"Fv" is the minimum antibody fragment which contains a complete antigen(cid:173)
`
`recognition and antigen-binding site. This region consists of a dimer of one heavy chain and
`
`5
`
`one light chain variable domain in tight, non-covalent association. It is in this configuration
`
`that the three hypervariable regions of each variable domain interact to define an antigen(cid:173)
`
`binding site on the surface of the VwVL dimer. Collectively, the six hypervariable regions
`
`confer antigen-binding specificity to the antibody. However, even a single variable domain
`
`( or half of an Fv comprising only three hypervariable regions specific for an antigen) has the
`
`10
`
`ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
`
`The Fab fragment also contains the constant domain of the light chain and the first
`
`constant domain (CHI) of the heavy chain. Fab' fragments differ from Fab fragments by the
`
`addition of a few residues at the carboxy terminus of the heavy chain CH 1 domain including
`
`one or more cysteines from the antibody hinge region. Fab' -SH is the designation herein for
`
`15
`
`Fab' in which the cysteine residue(s) of the constant domains bear at least one free thiol
`
`group. F(ab')2 antibody fragments originally were produced as pairs ofFab' fragments
`
`which have hinge cysteines between them. Other chemical couplings of antibody fragments
`
`are also known.
`
`In some embodiments, particular antibodies or molecules arc used in the methods of
`
`20
`
`the invention. For example, exemplary antibodies include HER2 antibodies including
`
`trastuzumab (HERCEPTIN(Bl) (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285-4289
`
`(I 992), U.S. Patent No. 5,725,856) and pertuzumab (OMNIT ARG™) (WOOl/00245); CD20
`
`antibodies (see below); IL-8 antibodies (St John et al., Chest, 103:932 (1993), and
`
`International Publication No. WO 95/23865); VEGF or VEGF receptor antibodies including
`
`25
`
`humanized and/or affinity matured VEGF antibodies such as the humanized VEGF antibody
`
`huA4.6.1 bevacizumab (A VAST IN(&) and ranibizumab (LUCENTIS®) (Kim et al., Growth
`
`Factors, 7:53-64 (1992), International Publication Nos. WO 96/30046 and WO 98/4533 I);
`
`PSCA antibodies (WOOl/40309); CD40 antibodies, including S2C6 and humanized variants
`
`thereof(W000/75348) and TNX 100 (Chiron/Tanox); CD11a antibodies including
`
`30
`
`efalizumab (RAPTIVA®) (US Patent No. 5,622,700, WO 98/23761, Steppe et al., Transplant
`
`Intl. 4:3-7 (1991), and Hommant et al., Transplantation 58:377-380 (1994)); antibodies that
`
`bind IgE including omalizumab (XOLAIR(ID) (Presta et al., J. Jmmunol. 151 :2623-2632
`
`7
`
`Regeneron Exhibit 1029.008
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`(1993), and International Publication Nos. WO 93/04173, WO 95/19181, and WO 99/01556;
`
`US Patent Nos. 5,091,313 and 5,714,338); CD18 antibodies (US Patent No. 5,622,700, or as
`
`in WO 97 /26912); Apo-2 receptor antibody antibodies (WO 98/51793); TNF-a antibodies
`
`including cA2 or infliximab (REMICADE®), CDP571, MAK-195, adalimumab
`
`5
`
`(HUMIRA™), CDP-870 (Celltech), anti-TNF-a polyclonal antibody (e.g. PASSTNF-a™;
`
`Verigen); Tissue Factor (TF) antibodies (European Patent No. 0 420 937 B 1 ); a4-a7 integrin
`
`antibodies (WO 98/06248); EGFR antibodies (chimerized or humanized 225 antibody,
`
`cetuximab (ERBUTIX®; TmClone; WO 96/40210) or panitumumab (VECTTBTX™;
`
`Amgen)); CD3 antibodies such as OKT3 (US Patent No. 4,515,893); CD25 or Tac antibodies
`
`10
`
`such as CHI-621 (SIMULECTIBJ) and ZENAPAX1lt (US Patent No. 5,693,762); CD4
`
`antibodies such as the cM-7412 antibody (Choy et al., Arthritis Rheum 39(1):52-56 (1996));
`
`CD52 antibodies such as CAMPATH-lH (lLEX/Berlex) (Riechmann et al., Nature 332:323-
`
`337 (1988)); Fe receptor antibodies such as the M22 antibody directed against Fi;:Rl as in
`
`Graziano et al., J. Immunol. 155(10):4996-5002 (1995); an alpha 4 integrin antibody such as
`
`15
`
`natalizumab (ANTEGREN@) available from Biogen Idec/Elan; carcinoembryonic antigen
`
`(CEA) antibodies such as hMN-14 (Sharkey et al., Cancer Res. 55(23Suppl): 5935s-5945s
`
`(1995); antibodies directed against breast epithelial cells including huBrE-3, hu-Mc 3 and
`
`CHL6 (Ceriani et al., Cancer Res. 55(23): 5852s-5856s (1995); and Richman et al., Cancer
`
`Res. 55(23 Supp): 5916s-5920s (1995)); antibodies that bind to colon carcinoma cells such as
`
`20
`
`C242 (Litton et al., Eur. J. lmmunol. 26(1 ): 1-9 (1996)); CD38 antibodies, e.g. AT 13/5 (Ellis
`
`et al., J. Immunol. 155(2):925-937 (1995)); CD33 antibodies such as Hu Ml95 (Jurcic et al.,
`
`Cancer Res 55(23 Suppl):5908s-5910s (1995) and CMA-676 or CDP771; CD22 antibodies
`
`such as LL2 or epratuzumab (L YMPHOCIDERl; Immunomedics ), including epratuzumab Y-
`
`90 (Juweid et al., Cancer Res 55(23 Suppl):5899s-5907s (1995)), CD22 antibody (Abiogen,
`
`25
`
`Italy), CMC 544 (Wyeth/Celltech), combotox (UT Southwestern), BL22 (NIH), and
`
`LympoScan Tc99 (Immunomedics); EpCAM antibodies such as 17-lA (PANOREX@);
`
`Gpllb/Illa antibodies such as abciximab or c7E3 Fab (REOPRO®); RSV antibodies such as
`
`MEDl-493 (SYNAGlS®); CMV antibodies such as PROTOVlR®; HIV antibodies such as
`
`PR0542; hepatitis antibodies such as the Hep B antibody OST A VTR®; CA 125 antibody
`
`30 OvaRex; idiotypic GD3 epitope antibody BEC2; y3 antibody ( e.g. VIT AXIN:ID;
`
`Medimmune ); human renal cell carcinoma antibody such as ch-0250; ING-1; anti-human 17-
`
`1 A antibody (3622W94); anti-human colorectal tumor antibody (A33); anti-human
`
`melanoma antibody R24 directed against GD3 ganglioside; anti-human squamous-cell
`
`8
`
`Regeneron Exhibit 1029.009
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`carcinoma (SF-25); human leukocyte antigen (HLA) antibody such as Smart ID 10 and the
`
`anti-HLA DR antibody Oncolym (Lym-1); CD37 antibody such as TRU 016 (Trubion); IL-
`
`21 antibody (Zymogenetics/Novo Nordisk); anti-B cell antibody (Impheron); B cell targeting
`
`MAb (lmmunogen/ Aventis); ID09C3 (Morphosys/GPC); LymphoRad 131 (HGS ); Lym- I
`
`5
`
`antibody Y-90 (USC); LIF 226 (Enhanced Lifcsci.); BAFF antibody ( e.g., WO 03/33658);
`
`BAFF receptor antibody (e.g., WO 02/24909); BR3 antibody; Blys antibody such as
`
`belimumab; LYMPHOSTAT-B™; anti-Lym-I Oncolym (USC/Peregrine); ISF 154
`
`(UCSD/Roche/Tragen); gomilixima (Idec 152; Biogen Idec); IL-6 receptor antibody such as
`
`atlizumab (ACTEMRATM; Chugai/Roche); IL-15 antibody such as HuMax-Il-15
`
`10
`
`(Genmab/Amgen); chemokine receptor antibody, such as a CCR2 antibody ( e.g. MLN1202;
`
`Millennium); anti-complement antibody, such as C5 antibody ( e.g. eculizumab, 5G 1.1;
`
`Alexion); oral formulation of human immm10globulin (e.g. lgPO; Protein Therapeutics); IL-
`
`12 antibody such as ABT-874 (CAT/Abbott); and Tencliximab (BMS-224818). In some
`
`embodiments, the antibody herein is ranibizumab.
`
`15
`
`Examples of CD20 antibodies include: "C2B8," which is now called "rituximab"
`
`("RTTUXAN(JZI'') (US Patent No. 5,736,137); the yttrium-[90]-labelled 2B8 murine antibody
`
`designated "Y2B8" or "lbritumomab Tiuxetan" (ZEV ALIN®) commercially available from
`
`IDEC Pharmaceuticals, Inc. (US Patent No. 5,736,137; 2B8 deposited with ATCC under
`
`accession no. HBI 1388 on June 22, 1993); murine IgG2a "Bl," also called 'Tositumomab,"
`optionally labelled with 131 I to generate the " 131 I-B l" or "iodine I 131 tositumomab" antibody
`
`20
`
`(BEXXARTM) commercially available from Corixa ( see, also, US Patent No. 5,595,721);
`
`murine monoclonal antibody "1F5" (Press et al., Blood 69(2):584-591 (1987) and variants
`
`thereof including "framework patched" or humanized 1F5 (WO 2003/002607, Leung, S.;
`
`ATCC deposit HB-96450); murine 2H7 and chimeric 2H7 antibody (US Patent No.
`
`25
`
`5,677,180); humanized 2H7 (WO 2004/056312, Lowman et al., and as set forth below); 2F2
`
`(HuMax-CD20), a fully human, high-affinity antibody targeted at the CD20 molecule in the
`
`cell membrane ofB-cells (Genmab, Denmark; see, for example, Glennie and van de Winkel,
`
`Drug Discovery Today 8: 503-510 (2003) and Cragg et al., Blood 101: 1045-1052 (2003);
`
`WO 2004/035607; US2004/0167319); the human monoclonal antibodies set forth in WO
`
`30
`
`2004/035607 and US2004/0167319 (Teeling et al.); the antibodies having complex N(cid:173)
`
`glycoside-linked sugar chains bound to the Fe region described in US 2004/0093621 (Shitara
`
`et al.); monoclonal antibodies and antigen-binding fragments binding to CD20 (WO
`
`2005/000901, Tedder et al.) such as HB20-3, HB20-4, HB20-25, and MB20-l l; CD20
`9
`
`Regeneron Exhibit 1029.010
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`binding molecules such as the AME series of antibodies, e.g., AME 33 antibodies as set forth
`
`in WO 2004/103404 and US2005/0025764 (Watkins et al., Eli Lilly/Applied Molecular
`
`Evolution, AME); CD20 binding molecules such as those described in US 2005/0025764
`
`(Watkins et al.); A20 antibody or variants thereof such as chimeric or humanized A20
`
`5
`
`antibody (cA20, hA20, respectively) or IMMU-106 (US 2003/0219433, Immunomedics);
`
`CD20-binding antibodies, including epitope-depleted Leu- I 6, 1H4, or 2B8, optionally
`
`conjugated with IL-2, as in US 2005/0069545Al and WO 2005/ 16969 (Carr et al.); bispecific
`
`antibody that binds CD22 and CD20, for example, hLL2xhA20 (W02005/14618, Chang et
`
`al.); monoclonal antibodies L27, 028-2, 93-IB3, B-Cl orNU-B2 available from the
`
`10
`
`International Leukocyte Typing Workshop (Valentine et al., In: Leukocyte Typing III
`
`(McMichael, Ed., p. 440, Oxford University Press (1987)); 1H4 (Haisma et al., Blood 92: 184
`
`(1998)); anti-CD20 auristatin E conjugate (Seattle Genetics); anti-CD20-IL2
`
`(EMD/Biovation/City of Hope); anti-CD20 MAb therapy (EpiCyte ); anti-CD20 antibody
`
`TRU 015 (Trubion). The preferred CD20 antibodies herein are chimeric, humanized, or
`
`15
`
`human CD20 antibodies, more preferably rituximab, humanized 2H7, 2F2 (Hu-Max-CD20)
`
`human CD20 antibody (Genmab), and humanized A20 antibody (Tmmunomedics).
`
`In some embodiments, a "hormone" is used in the methods of the invention. This
`
`generally refers to polypeptide hormones, which are generally secreted by glandular organs
`
`with ducts. Included among the hormones are, for example, growth hormone such as human
`
`20
`
`growth hormone, N-methionyl human growth hormone, and bovine growth hormone;
`
`parathyroid hormone; thyroxine; insulin; proinsulin; rclaxin; estradiol; hormone-replacement
`
`therapy; androgens such as calusterone, dromostanolone propionate, epitiostanol,
`
`mepitiostane, or testolactone; prorelaxin; glycoprotein hormones such as follicle stimulating
`
`hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH);
`
`25
`
`prolactin, placental lactogen, mouse gonadotropin-associated peptide, gonadotropin-releasing
`
`hormone; inhibin; activin; mullerian-inhibiting substance; and thrombopoietin. As used
`
`herein, the term hormone includes proteins from natural sources or from recombinant cell
`
`culture and biologically active equivalents of the native-sequence hormone, including
`
`synthetically produced small-molecule entities and pharmaceutically acceptable derivatives
`
`30
`
`and salts thereof.
`
`In some embodiments, a "growth factor" is used in the methods of the invention. This
`
`generally refers to proteins that promote growth, and include, for example, hepatic growth
`
`factor; fibroblast growth factor; vascular endothelial growth factor; nerve growth factors such
`
`10
`
`Regeneron Exhibit 1029.011
`
`

`

`WO 2008/077155
`
`PCT/US2007 /088728
`
`as NGF-~; platelet-derived growth factor; transforming growth factors (TGFs) such as TGF-a
`
`and TGF-~; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors;
`
`interferons such as interferon-a,-~, and -y; and colony stimulating factors (CSFs) such as
`
`macrophage-CSP (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF
`
`5
`
`(G-CSF). As used herein, the term growth factor includes proteins from natural sources or
`
`from recombinant cell culture and biologically active equivalents of the native-sequence
`
`growth factor, including synthetically produced small-molecule entities and pharmaceutically
`
`acceptable derivatives and salts thereof.
`
`In some embodiments, non-polypeptide compounds are used in the methods of the
`
`10
`
`invention. These include, e.g., pegaptanib (MACUGEN(ID; Eyetech Pham1aceuticals),
`
`steroids, and compounds used for RNA-interference mediated therapy.
`
`As used herein, a "pharmaceutical composition" is a solution comprising a compound
`
`which is suitable for administration to a subject. Pham1aceutical compositions according to
`
`the invention may be obtained by mixing the compound with optional physiologically
`
`15
`
`acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th
`
`edition, Osol, A. Ed. (1980)), in the form of aqueous solutions, lyophilized or other dried
`
`formulations. Acceptable carriers, excipients, or stabilizers are nontoxic to subjects at the
`
`dosages and concentrations employed, and may include buffers such as phosphate, citrate,
`
`and other organic acids; antioxidants including ascorbic acid and methionine;